Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Otterstad JE, Ford I. Otterstad JE, et al. Among authors: ford i. Eur J Heart Fail. 2002 Aug;4(4):501-6. doi: 10.1016/s1388-9842(02)00099-5. Eur J Heart Fail. 2002. PMID: 12167391 Free article. Clinical Trial.
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, Remme W, Sharpe DN, Ford I. McMurray J, et al. Among authors: ford i. J Am Coll Cardiol. 2005 Feb 15;45(4):525-30. doi: 10.1016/j.jacc.2004.09.076. J Am Coll Cardiol. 2005. PMID: 15708698 Free article. Clinical Trial.
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: ford i. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease.
Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, Cunningham T, Bezlyak V, Ford I, Dargie HJ, Oldroyd KG. Watkins S, et al. Among authors: ford i. Circulation. 2009 Dec 1;120(22):2207-13. doi: 10.1161/CIRCULATIONAHA.109.872358. Epub 2009 Nov 16. Circulation. 2009. PMID: 19917885 Clinical Trial.
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.
Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Preiss D, et al. Among authors: ford i. JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439. JAMA. 2012. PMID: 22910758
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.
Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, Hou YR, Pitt B, Dargie HJ, Ford I, Kjekshus J, Zannad F, Dickstein K, McMurray JJ. Inglis SC, et al. Among authors: ford i. Int J Cardiol. 2013 Sep 30;168(2):1094-101. doi: 10.1016/j.ijcard.2012.11.033. Epub 2012 Nov 26. Int J Cardiol. 2013. PMID: 23194780
812 results